Valemetostat Tosylate, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Valemetostat Tosylate clinical trials

A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial of Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in Participants with Advanced or Metastatic Non-small Cell Lung Cancer whose Tumors Express PD-L1 with Tumor Proportion Score ≥50% Without Actionable Genomic Alterations

This study looks at a new drug, Valemetostat Tosylate, combined with Pembrolizumab (Keytruda) for advanced lung cancer. It compares this combination to Keytruda alone in people whose cancer has a specific marker and hasn't spread to other parts of the body.